Explore ACADIA Pharmaceuticals' Q2 2025 earnings highlights, featuring strong revenue growth, DAYBUE expansion, NUPLAZID guidance raise, and robust ...

ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.

Among adults with obstructive sleep apnea, a combination of pimavanserin and atomoxetine taken for 1 week “greatly” lowered ...